Psoriatic Arthritis

Using a cut-off value of 7.1 kPA for liver stiffness, results of the transient elastography yielded 100% sensitivity and 68% specificity among this patient population.

Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.

Post-treatment with risankizumab, the cDAPSA score, PGA score, and PASI score substantially decreased among a cohort of patients with psoriatic arthritis.

A pooled analysis revealed a loading-dose regimen, especially for patients receiving secukinumab 150 mg for PsA, increases the odds of disease improvement.

This post-hoc analysis of phase 3 data, using GRAPPA-recognized PsA domains, highlighted disease improvements following treatment with guselkumab.

Despite these conclusions, this meta-analysis also showed that those receiving PDE4 inhibitors were the least likely to report adverse events.

Philip J Mease, MD, highlights recent data comparing the safety and efficacy of bimekizumab with other DMARDs for the treatment of PsA.

Patients with higher disease activity reported the highest perceived consequence of disease.

This month’s rheumatology month in review showcases the efficacy of various medications for the treatment of psoriatic arthritis, underscores the importance of addressing workforce challenges, and explores non-pharmacological interventions.

Dermatologist and rheumatologist Saakshi Khattri highlights the importance of screening psoriasis patients for psoriatic arthritis and how that may impact treatment decisions.

The selective, allosteric tyrosine kinase 2 inhibitor demonstrated significant and clinically meaningful improvements in PROs versus placebo in a phase 2 trial of patients with PsA.

These data highlight the changes observed in cytokine levels among both PsA treatment responders and non-responders.

Bimekizumab initiation resulted in greater or comparable efficacy regarding minimal disease activity and achievement of ACR50/70 compared with guselkumab.

Compared with RA, patients with PsA had a higher diagnostic delay and a greater time between the onset of symptoms and the start of treatment.

These data suggest risankizumab was both safe and efficacious through 100 weeks for PsA patients, with no new safety signals.

These data from the DISCOVER-2 study highlight improvements in patient-reported outcomes for patients who are biologic-naïve and have PsA.

This analysis indicates that a combined, 22-week Mediterranean and ketogenic diet for patients with psoriatic disease led to beneficial results.

These data highlight the potential window of opportunity for PsA patients’ diagnoses and any patient characteristics of those with longer diagnostic delays.

The findings in this research letter allow for greater understanding of residual joint pain modulators, with the overall goal being to improve health outcomes for those with PsA.

These data on patients with psoriatic arthritis point to risk levels for new adalimumab users as well as users of ustekinumab and etanercept.

A new study found the achievement of remission or low disease activity for PsA patients on apremilast was 53.8% by month 12.

On March 11, 2024, Acelyrin Inc. announced new positive data from clinical trial programs examining their IL-17A inhibitor izokibep in patients psoriatic arthritis and hidradenitis suppurativa.

Both biologic-naïve and biologic-experience patients receiving guselkumab demonstrated significantly higher ACR20 when compared with ustekinumab.

A real-world cohort of patients with treatment-resistant active psoriatic arthritis receiving 6 months of guselkumab treatment achieved clinically meaningful improvements in pain and physical function.

At week 24, patients with moderate to severe PsA receiving risankizumab had a significantly higher ACR20 response rate when compared with placebo.